OSR (NASDAQ:OSRH – Get Free Report) is one of 89 public companies in the “UNCLASSIFIED” industry, but how does it contrast to its peers? We will compare OSR to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.
Institutional and Insider Ownership
55.3% of OSR shares are held by institutional investors. Comparatively, 52.0% of shares of all “UNCLASSIFIED” companies are held by institutional investors. 60.6% of OSR shares are held by company insiders. Comparatively, 42.9% of shares of all “UNCLASSIFIED” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and price targets for OSR and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OSR | 1 | 0 | 0 | 0 | 1.00 |
| OSR Competitors | 206 | 262 | 217 | 3 | 2.02 |
Profitability
This table compares OSR and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OSR | N/A | -12.19% | -8.18% |
| OSR Competitors | 0.86% | 0.95% | 0.80% |
Earnings and Valuation
This table compares OSR and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| OSR | N/A | -$2.41 million | -0.67 |
| OSR Competitors | $48.56 million | -$19.62 million | 95.99 |
OSR’s peers have higher revenue, but lower earnings than OSR. OSR is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
OSR has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, OSR’s peers have a beta of -0.08, suggesting that their average share price is 108% less volatile than the S&P 500.
Summary
OSR peers beat OSR on 9 of the 13 factors compared.
About OSR
OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.
Receive News & Ratings for OSR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OSR and related companies with MarketBeat.com's FREE daily email newsletter.
